You are here: cherry > Press releases for September 2010 > Secured Life Fund launches to Swiss, Japanese, Korean and Hong Kong markets - new asset class offering fixed annual returns

13 September 2010

Stable and consistent returns - 5, 7 & 10 year Bonds paying from 8 – 9 % p/a Min €250k investment – for institutional and pension fund investors Global distribution: Switzerland up first, to be followed by a further rollout to Japan, Hong Kong and Korea. SECURED LIFE FUND is embarking on a major global marketing programme, targeting institutional investors in Switzerland, Japan, Korea and Hong Kong. Designed primarily for institutional investors, the fund is constructed to produce regular cash flows without the volatility of stock markets or other traditional benchmarks. Investors into the fund will be able to choose from either a 5, 7 or 10 year investment periods, each of which will provide fixed returns paid annually in arrears. Returns range from 7.5% for the five year bond, 8% over 7 years, rising to 9% for the 10 year bond. Income is generated by investing in a combination of cash, cash equivalent assets and principally through the repayment of loans collateralised by US life insurance policies. The minimum investment is currently Euro 250,000, but there are plans to roll out the Fund for smaller sum investments. “The Secured Life Fund has worked extremely well in the US, where the asset class was pioneered,” said finance director Andrew Walters. “The time is right to deliver this asset class to new key territories in Asia and Europe and our research indicates a pent up demand for an investment class offering steady returns. “A major attraction for Swiss, Japanese, Korean and Hong Kong-based institutional investors is the fact that they can enjoy stable and consistent returns which currently outgun most other asset classes. “We have started our Swiss marketing programme – which will shortly be followed by the Asian territories – we will then look to roll out to Middle Eastern and South African investors. “Given the continuing muted returns from equities and other income producing vehicles such as corporate bonds and gilts, our product is perfectly suited to international investors wanting certainty of returns over given periods,” he said. “It is a tried and tested model, listed on the Irish Stock Exchange, and properly vetted by medical oncologists. These medical professionals and other medical school faculty physicians, acting as independent contractors, are key to the underwriting process. “Insurance companies providing the client’s policy must be rated ‘A’ or better by Standard & Poor’s, and of course the policy must mature on the death of the potential customer,” added Walters.

Click below to download the full press release